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Abstract 
  
The HLA is the main genetic determinant of multiple sclerosis (MS) risk. Within the 
HLA, the class II HLA-DRB1*15:01allele exerts a disease promoting effect, whereas 
the class I HLA-A*02 allele is protective. The CIITA gene is crucial for expression of 
class II HLA molecules and has previously been found to associate with several 
autoimmune diseases, including MS and Type 1 diabetes.  
We here performed association analyses with CIITA in 2000 MS cases and up to 
6900 controls as well as interaction analysis with HLA. We find that the previously 
investigated single nucleotide polymorphism rs4774 is associated to MS risk in cases 
carrying the HLA-DRB1*15 allele (p=0.01, OR=1.21, 95%CI: 1.04-1.40) or the HLA-
A*02 allele (p=0.01, OR=1.33, 95%CI=1.07-1.64) and that these associations are 
independent of the adjacent confirmed MS susceptibility gene CLEC16A. We also 
confirm interaction between rs4774 and HLA - -DRB1*15:01 such that individuals 
carrying the risk allele for rs4774 and HLA-DRB1*15:01have a higher than expected 
risk for MS. 
In conclusion, our findings support previous data that variability in the CIITA gene 
affects MS risk, but also that the effect is modulated by MS-associated HLA 
haplotypes. These findings further underscore the biological importance of HLA for 
MS risk. 
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Introduction: 
Accumulating evidence support the notion that Multiple Sclerosis (MS) is primarily an 
autoimmune disease, characterized by lesions in the brain and spinal cord caused by 
demyelination as a result of periodical infiltration of auto reactive immune cells. This 
leads to a progressive accumulation of sclerotic plaques where nerve axons are 
damaged, in turn leading to increasing neurological disability. Typically the disease 
starts in early adulthood and is more common in women1. 
The HLA region on chromosome 6 has been established as the main genetic risk 
determinant area for MS, with the strongest disease promoting effect exerted by  
class II DRB1*15:01 2,3, while the class I A*02 allele has been associated with 
reduced risk4,5. However, the disease etiology of MS is complex and several other 
genes as well as environmental factors provide additional influences on disease risk 
4,6. 
The CIITA gene (16p13) is of particular interest as a candidate gene for several 
autoimmune diseases, since the encoded protein functions as an assembler of the 
transcription factors necessary for transcription of major histocompability complex 
class II (MHCII) molecules. The essential function of CIITA is evident in Bare 
Lymphocyte Syndrome (BLS), a rare condition characterized by lack of MHC class II 
molecules associated with severe immunodeficiency7 (OMIM 9920). In addition, 
CIITA may also be involved in the regulation of expression of class I molecules as 
well as other genes in immune cells 8; 9. The CIITA gene is controlled by four 
independent and cell type specific promoters (PI-PIV), and the gene product 
expressed from promotor III is the one mostly investigated, since it is used in B-cells, 
activated T cells and plasmacytoid dendritic cells. The promotor I (PI) mainly controls 
CIITA expression in myeloid dendritic cells and macrophages. Promotor IV is used in 
a variety of cells, among them thymic epthelial cells, while the promoter II (PII) is of 
unknown function in humans 10. 
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Variability in the CIITA gene has been reported to be associated to several diseases, 
among them MS11, Myocardial Infarction (MI)11 Rheumatoid Arthritis (RA)11,12, Type 1 
Diabetes (T1D) 13, Addison’s disease 14 and Celiac disease 15, but lack of association 
have also been reported in several studies 16,17,18  and association has not always 
been possible to reproduce in different populations. We have recently shown that the 
allele frequency of CIITA markers vary with age in a large pooled material of 
individuals used as controls in different genetic association studies13. It is therefore 
possible that contradictory findings regarding any possible association between 
CIITA and disease risk at least in part can be explained by insufficient matching for 
age between patients and controls.   
 
Various SNPs in the CIITA gene have been associated with MS risk. Thus, 
Swanberg et al reported association to rs3087456 and also decreased expression of 
MHC class II after stimulation of leukocytes with interferon-γ for the minor allele of 
rs3087456 11. Bronson et al found association to MS for marker rs4774, particularly in 
DRB1*15:01 positive individuals, but could not reproduce the finding of the 
rs3087456 SNP19. 
 
In this study we investigate the possible association of several SNPs in the CIITA 
gene to MS, among them the earlier reported rs4774 and rs3087456, as well as the 
interaction with DRB1*15 and A*02, taking care to correct for variation in age. 
We test the association both in the whole cohort of cases and controls, and after 
stratification for DRB1*15 and A*02. 
We initially found association for rs4774, which was stronger when stratifying  for the 
presence of DRB1*15 and A*02, respectively. Also, interactions between the CIITA 
marker and HLA alleles both on the multiplicative scale and on the additive scale 
were detected.  
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Results: 
SNP markers in the CIITA gene were selected based on prior reports of association 
to MS (rs3087456, rs4774) and our previous study of CIITA in T1D13.  
First, we performed an univariate association analysis between CIITA markers and 
MS in the combined material of 2000 MS patients and up to 6900 controls from 
studies of MS, RA, MI and T1D (supplementary table 1), based on presence of minor 
allele versus major allele homozygotes. A significant association of rs4774 (p=0.01) 
was discovered in this analysis (table1).  
We have previously shown that the frequency of genotypes within the CIITA gene 
varies with age among controls, and therefore matching for age among cases and 
controls should be considered in association studies 13. In a logistic regression model 
with age as a covariate, the association to MS remained for rs4774 (p=0.01, OR 
1.17, CI: 1.03-1.31) (table 1). None of the other CIITA markers where associated to 
MS in any of these analyses.  
Bronson et al 19 found a stronger association to MS for the rs4774 marker with 
stratification for presence of the main disease associated class II haplotype 
DRB1*15:01. We therefore investigated rs4774 both when all individuals were 
stratified for HLA-DRB1*15 but also when all individuals were stratified for HLA-A*02, 
and corrected for age with logistic regression.  
In the DRB1*15 positive cohort (977 cases, 932 controls), association for rs4774 
(p=0.03, OR: 1.23, 95%CI: 1.02 - 1.49) was observed  (table 2), but we also detected 
a suggestive association to MS for rs3087456 minor allele homozygotes (1011 cases 
and 1154 controls, p=0.07) (data not shown).  None of the other investigated CIITA 
SNPs were associated among DRB1*15 stratified individuals. We also investigated if 
there was any association between SNPs in CIITA and DRB1*15 among the controls, 
but found no such association (data not shown). 
7 
 
When the material was stratified in the same manner for absence of DRB1*15, no 
association was found between CIITA and MS among DRB1*15 negative individuals 
(table 2). 
The same analysis was performed in cohorts stratified for presence or absence of 
HLA-A*02. We here found that rs4774 was associated to MS in cases stratified for 
HLA-A*02 (650 cases, 757 controls, p=0.01, OR 1.33, 95%CI: 1.07-1.64), but not in 
the absence of HLA-A*02 (table 2). No other marker showed significant association 
in these cohorts. We also found association between A*02 and rs4774 among the 
controls, with homozygotes for the minor allele being more common among those 
who lack A*02 (p=0.02). 
When we investigated the interaction between HLA and CIITA we detected 
multiplicative interaction for rs4774 – HLA*A2 (p=0.03, OR: 1.40, 95%CI: 1.02-1.90) 
and additive interactionfor rs4774- DRB1*15 (AP:0.17, 95%CI: 0.01-0.33,  p=0.04) 
(fig.1). The detected interaction suggests that for individuals who carry the DRB1*15 
haplotype, the minor allele of rs4774 exerts an increased risk. 
Four markers in the nearby CLEC16A gene, an established MS risk gene 20,21, were 
included in the analyses to rule out that any association in CIITA was due to linkage 
disequilibrium (LD) with this gene. The SNPs have been reported in genome-wide 
association studies20; 22 and lately in the MS Immunochip study23 as the strongest 
associated markers to MS in the CLEC16A gene. In our material, all of the four 
CLEC16A markers where significantly associated to MS (table 1), and the 
association to rs4774 remained significant (p<0.05) when adding them to the logistic 
regression model. We also performed an LD plot (fig.2) demonstrating a low LD 
between the markers in the two genes (r2≤0.04). 
 
Finally, we conducted a meta-analysis on the material presented here and that of 
Bronson et al19 with stratification of cases for the presence of DRB1*15 (fig.3). In this 
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analysis the association found by us is weaker than the association Bronson et al 
found in their cohorts, but goes in the same direction and the combined OR is 1.3 
(95%CI: 1.15-1.42) for presence of the minor allele (CC, CG) versus major allele 
homozygotes (GG). 
 
Discussion:  
We here replicate the previous findings11; 19 of an association between genetic 
variability in CIITA and MS risk. Based on the biological function the CIITA gene is a 
particularly interesting candidate gene in autoimmune diseases, considering its 
crucial role in regulating the expression of MHCII molecules, in turn the main genetic 
determinant of disease risk. The MHCII molecules are central in antigen presentation 
to lymphocytes, but also for presenting self-proteins and contributing to maintaining 
immunological tolerance. The DRB1 locus in the HLA class II region is the major 
established genetic determinant of disease risk in MS, which makes interaction 
between these loci plausible for any possible association to the CIITA gene. 
Experimental studies also suggest that CIITA is involved in the regulation of  MHCI 
genes, as well as other immune genes, making additional associations possible 9; 24. 
 
In previous studies variability in the CIITA gene have been reported to be associated 
to several autoimmune diseases. However, negative studies failing to replicate these 
results have also been published 16-18. These contradictory findings may depend on 
heterogeneity in case-control studies, technical issues and on how the control groups 
were chosen. We have recently shown that there is a variation in allele frequencies 
for markers in CIITA depending on age among a large pooled cohort of controls used 
in genetic association studies13. Thus, lack of age matching between cases and 
controls may affect the results in association studies. The earlier reported rs3087456 
marker in CIITA is one such marker on which there has been a controversy and 
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contradictive results in different studies. In the current study we could not find any 
association to this marker in the present cohort. However, when we stratified both 
cases and controls for DRB1*15 and corrected for age in logistic regression, we 
detected a tendency towards association to MS for the minor allele homozygote for 
this marker (p=0.07, data not shown). In addition, the initial association of rs4774 to 
MS in univariate analysis, was strengthened when we stratified cases for DRB1*15 or 
A*02 haplotype. Earlier studies (except Bronson et al) have not taken into account 
the effect of HLA haplotypes in the investigated material, and this likely have 
influence on the results given the biological function of CIITA. 
CLEC16A is a well established risk gene for MS that map close to the CIITA gene20; 
21. It has been shown that the association to MS for these two genes are independent 
of each other 19, and the relationship between CIITA and CLEC16A has been 
investigated thoroughly, revealing a low degree of linkage disequilibrium between the 
genes25, which also is confirmed in our material (r2≤0.04) (fig.2). 
The significance level of the observed association for rs4774 to MS in our material is 
modest and does not reach genome-wide significance. No SNPs in CIITA has been 
reported as associated to MS in genome-wide studies. However, given the complex 
nature of the etiology of MS, genes with low or moderate effect are believed to affect 
the disease as well. When we performed a meta analysis with our and Bronsons data 
the effect was in the same direction, which supports a role for CIITA in MS 
susceptibility.  
When performing genetic association studies it is important to consider the effect of 
population stratification. In this study we do not have genome wide SNP genotypes 
for all our samples, which would have allowed us to perform principal component 
analysis (PCA). Instead, we have removed all individuals with known non-
Scandinavian descent, and when PCA analysis was possible we have removed 
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outliers. It should also be pointed out that all individuals are resident in Sweden and 
collected from Swedish clinics, which should increase the ethnic homogeneity. 
The physical relevance of the association of this CIITA marker depending on 
DRB1*15 and A*02 is unknown; possibly it could have effect on the function of the 
CIITA gene and subsequently on MHCI and II expression, which in turn have 
different outcomes depending on what HLA allele an individual carries. Swanberg et 
al 11 found a lower expression of the CIITA gene and lower levels of MHCII 
transcripts for individuals with the minor allele homozygote (GG) genotype of CIITA- 
marker rs3087456 in stimulated peripheral blood mononucleated cells( PBMCs) as 
compared to other genotypes. The LD between rs3087456 and rs4774 is low so we 
cannot conclude that rs4774 affect expression of MHCII from this study. Nor is 
rs4774 situated in a promotor region, but it is a missense mutation, causing amino-
acid change from glycine to alanine. How this will affect the expression of the CIITA 
gene and the function of the CIITA protein remains unclear. Further experiments are 
needed to test this hypothesis.  
It can be argued that variability in expression of the strongly associated HLA 
haplotype DRB1*15 could have an effect on MS susceptibility, whereas variation in 
the expression of HLA haplotypes not associated to MS does not affect MS 
susceptibility. 
The MHCII molecule is important both for T-cell selection in the thymus as well as for 
antigen recognition in the periphery. There are several mechanisms by which a 
change in MHCII expression could affect disease susceptibility, for example through 
lack of tolerance induction in T-cells, influenced effect on regulatory T-cells or less 
effective clearing of pathogens that could play a role in disease onset 26.The MHC 
class I molecules are mainly involved in presenting intracellular pathogens, such as 
viruses. Indeed, there are now evidence that certain viruses, for example Epstein-
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Barr virus (EBV), modify MS disease risk27,28 . In contrast, infection with 
cytomegalovirus (CMV) may result in a lowered MS risk 29; 30. 
It is also possible that different HLA class I alleles influence the immune response 
depending on the efficiency of clearance of infection of MS associated viruses or by 
inducing tolerance in auto-reactive T-cells5. Further efforts directed at replicating the 
current findings and dissecting the mechanistic basis for how the polymorphisms 
studied affect CIITA function, and subsequently autoimmune responses, are needed 
to clarify the role of genetic variability in the CIITA gene.  
 
Material and Methods: 
Ethics Statement: 
All included patient and control materials and analyses in this study were approved 
by the Regional Ethical Review Boards in the cities of Stockholm, Lund and Umeå in 
Sweden (www.epn.se). Informed consent from all study participants or their parents 
was obtained. Investigations were carried out according to guidelines from the 
Declaration of Helsinki. 
 
Subjects: Multiple Sclerosis patients and controls  
The multiple sclerosis patients are collected from the study cohorts described below, 
in total 2003 Swedish MS patients and 1672 controls (not all patients or controls were 
typed for all markers, see supplementary table 1). All MS cases has been diagnosed 
either according to McDonald’s31 or Poser’s criteria32, and individuals of known non-
Scandinavian origin were excluded from the current study.  
 
The Epidemiological Investigation of Multiple Sclerosis (EIMS): 
A population based nation-wide case-control cohort with incident cases of MS which 
has been described previously 33. The controls were randomly selected from the 
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national population register and matched to the case’s sex, age and residential area, 
625 cases and 475 controls from this group were used in the current study. 
 
The Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) cohort:  
The cohort consists exclusively of cases (n=318) with relapsing-remitting MS from 
clinics throughout Sweden, that are being treated with natalizumab34. 
 
The Stockholm Multiple Sclerosis cohort (STOP MS) :  
The patients fulfilled the McDonald criteria 31 for definite multiple sclerosis and were 
recruited by neurologists at the Karolinska University Hospital Huddinge and Solna 
sites in Stockholm, Sweden. The patients in the cohort were between 22 and 91 
years of age and the controls were matched for ethnicity and constitutes of blood 
donors between 21 and 76 years of age. 1060 cases and 1197 controls were used 
from this group. All patients and controls originating from Sweden or other Nordic 
countries 35. 
 
Extra controls:  
To further increase the power of the analyses extra control cohorts were included 
from previous studies of RA, T1D and MI (not all controls were typed for all markers, 
see supplementary table 1.) 
 
Rheumatoid arthritis: 
1426 healthy controls matched to RA patients by age, sex and residential area.  The 
recruitment of affected individuals and controls was described previously in 
connection with EIRA study 36. 97% of the study population was of self-reported 
Caucasian origin. No chronic diseases were reported among these controls. 
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Individuals deviating in a principal component analysis (PCA) or of known non-
Scandinavian origin were excluded from the current study37. 
 
Type 1 diabetes- Diabetes Incidence in Sweden (DISS1): 
The DISS1 controls consists of 618 sex, age and residence matched, healthy 
individuals to T1D patients, aged 15-34 years old and diagnosed with diabetes 
between 1987 and 1989, all from Sweden DISS registry 38.  
 
Type 1 diabetes- Diabetes Incidence Study in Sweden (DISS2): 
The DISS2 controls consist of 836 age-and sex matched healthy controls to T1D 
patients aged 15-36 years old and collected during 1992 and 1993 from the DISS 
registry in Sweden 39. 
 
Type 1 diabetes- Swedish Childhood Study (Sv2): 
From the Swedish Childhood registry during 1986 and 1987, 476 controls to T1D 
patients were selected. The controls were geographically, gender and age matched 
to all cases of T1D in the cohort above 7 years of age (n=423). For patients under the 
age of 7 years a control was selected among patients being treated at the hospital for 
reasons other than T1D (n=53) 40.  
 
Type 1 diabetes- Diabetes Registry in Southern Sweden (DR) 
Totally 2312 healthy controls from this study where included, 1695 men and 617 
women between 45 and 75 years of age 41. Individuals of known non-Scandinavian 
origin were excluded (n=100). 
 
Myocardial infarction (MI) – SCARF 
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From the SCARF 42 study of MI the control group consists of 387 healthy persons 
between 40-60 years of age, sex- and age-matched for the MI cases and recruited 
from the general population, of self-reported Caucasian origin. 
 
In this study, there is a partial overlap of cases and controls with a previously 
published MS study 11 for the Stockholm MS cohort (548 cases, 528 controls), the RA 
cohort (709 controls) and the MI cohort (387 controls). All individuals with known non-
scandinavian descent have been removed from this study. 
 
Genotyping methods: 
For MS patients and controls all SNPs where genotyped with the allelic discrimination 
method for TaqMan ABI 7900 (Applied Biosystems, Inc ABI, Sweden) 43 except for 
markers rs3087456 and rs4774, where individuals in the Stockholm MS cohort 
included in our previous publication  were genotyped with MALDI-TOF as described 
11. 
In the DISS2 cohort the TaqMan ABI 7900 typing method was used for all markers 
except for rs4774 and rs3087456 for which the DASH method 44 was used.  
DISS1 and SV-2 cohorts were genotyped using the MassArray chip-based matrix-
assisted laser desorption/ionization time-of-flight mass spectrometer (Sequenom Inc., 
San Diego, CA, USA) using the HME chemistry as described 45.  
Controls from the DR study were genotyped with the TaqMan ABI method as above. 
In the RA and MI controls, rs3087456 were genotyped with 5´nuclease assays, and 
rs4774 with MALDI-TOF as described 11, remaining CIITA markers where genotyped 
with the TaqMan ABI method. 
Additional genotypes for rs4774 (81 cases, 227 controls) for individuals already in the 
study but lacking genotypes for this marker was retrieved from the ImmunoChip 
custom genotyping array.23 
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Genotyping methods for HLA DRB1*15 and A*02: 
The genotyping of DRB1*15  and A*02 in the MS cohorts, as well as the genotyping 
of DRB1*15  in RA and DISS2 cohorts, was performed by allele specific amplification 
as described earlier 46. 
In the DISS1 and SV2 cohorts DRB1*15 was genotyped by restriction fragment-
length polymorphism (RFLP) 47. 
For individuals also included in the MS Immunochip study23, we used imputated 
genotypes for HLA where we lacked this information, adding information regarding 
HLA-A*02 for 145 individuals and for HLA-DRB1*15 for 128 individuals. The 
imputation was performed using HLA*IMP:021248 based on single nucleotide 
polymorphisms (SNPs) genotyped on the Immunochip custom array49. 
The other cohorts have not been typed for HLA. 
In total, 1959 MS cases and 4407controls had data concerning HLA DRB1*15 status 
and 1905 cases and 1762 controls had data concerning A2 status. 
All HLA genotyping was performed at 2-digit level. HLA coding was defined as 
presence or absence of allele for DRB1*15 and A*02.  
 
Statistical analysis: 
Univariate association was tested using Pearson's Chi-squared test. Logistic 
regression analysis using generalized linear modeling was used in multivariate 
analysis when correcting for the effect of age on the CIITA association. Age group 8 
(35-39 years) was used as a reference group in the multivariate analysis. Interaction 
on the multiplicative scale was tested using logistic regression including both 
variables (a,b) investigated, as well as the interaction variable (a*b) and confounders 
(age).  
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To investigate additive interaction, departure from additivity was estimated by 
calculating attributable proportion (AP) due to interaction. The analysis was 
performed as described 50 using the generalized linear modeling (glm) in R and the 
vcov command to get the covariance matrix.  
A meta-analysis was performed using fixed effect Mantel–Haenszel analysis and 
Woolf’s test for heterogeneity in R using the meta.MH command in the rmeta 
package. No heterogeneity between groups was discovered. 
All statistical analyses where performed in the statistical computer program R 
2.14.151. 
The LD structure plot (fig.1) for investigated markers in the MS cohort was performed 
in Haploview 4.252 
Supplementary information is available at Genes&Immunity´s website. 
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Tables 
Table 1: SNP positions and association analysis for CIITA and CLEC16A in MS 
 
gene marker location/ chr position1 
Cases 
maf 
(total n) 
All 
controls 
maf 
(total n) 
Univariate 
analysis 
p-value2 
Multivariate 
analysis 
p-value3 
CIITA rs11074930 Before PI/ 10842650 
0,50 
(1466) 
0,50 
(2357) 0.46 0.38 
CIITA rs8052975 Before PI/ 10856764 
0,25 
(1709) 
0,25 
(3333) 0.37 0.46 
CIITA rs4781003 Before PI/ 10865178 
0,15 
(1620) 
0,16 
(3262) 0.35 0.32 
CIITA rs6416647 Between PI and PIII/ 10873098
0,27 
(1792)
0,28 
(3777) 0.35 0.42 
CIITA rs11074932 Between PI and PIII/ 10875837 
0,28 
(1889) 
0,28 
(3796) 0.82 0.96 
CIITA rs3087456 In PIII/ 10878403 0,23 (1786) 
0,24 
(6967) 0.09 0.12 
CIITA rs4774 
Exon (non-
synonymous) 
/10908349 
0,33 
(1714) 
0,31 
(3756) 0.01 0.01 
CLEC16A rs12708716 CLEC16A gene / 11087374
0,29 
(1984)
0,32 
(2464) 0.0005 9.34e-05 
CLEC16A rs12927355 CLEC16A gene / 11102272 
0.25 
(581) 
0.31 
(970) 0.0009 0.0003 
CLEC16A rs6498169 CLEC16A gene /11156830 
0,45 
(1201) 
0,40 
(1005) 0.004 0.0009* 
CLEC16A rs4780346 CLEC16A gene / 11196307 
0.34 
(581) 
0.28 
(970) 0.001 0.0009 
1 Location of SNP in relation to different promotor (PI-IV) of the CIITA gene. 
Chromosome position, genome build 36.3, contig NT 010393.15 (Reference sequence) 
2 presence of minor allele vs major allele homozygote using Pearson's Chi-squared test 
3 presence of minor allele vs major allele homozygote using logistic regression analysis including age 
(16 groups) as covariate.*minor allele homozygote 
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Table 2: Age-adjusted logistic regression analysis for testing association to rs4774 in HLA-
DRB1*15 and HLA-A*02 stratified cohorts 
  
1) Cases and controls stratified for presence (+) or absence (-) of HLA-DRB1*15 or HLA-A*02 
2) presence of minor allele vs major allele homozygote using logistic regression analysis 
including age (16 groups) as covariate 
  
DRB1*15+stratified1 freq case/cont (n) p-value2
 
OR, 95%CI 
Major allele homozygotes (GG) 42.5 (415) / 46,1 (430)  
Presence of minor allel (CG,CC) 57.5 (562)  / 53.9 (502) 0.03 1.23  (1.02-1.49) 
Total n case/cont 977 / 932  
DRB1*15-stratified1 freq case/cont (n) p-value OR, 95%CI 
Major allele homozygotes (GG) 44.2 (223) / 47.2 (1096)  
Presence of minor allel (CG,CC) 55.8 (281) / 52.8 (1228) 0.24 1.12 (0.92-1.38) 
Total n case/cont 504 / 2324   
A*02+stratified1 freq case/cont (n) p-value 
 
OR, 95%CI 
Major allele homozygotes (GG) 43.2 (281) / 49.4 (374)   
Presence of minor allel (CG,CC) 56.8 (369) / 50.6 (383) 0.010 1.33  (1.07-1.64) 
Total n case/cont 650 / 757   
A*02-stratified1 freq case/cont (n) p-value 
 
OR, 95%CI 
Major allele homozygotes (GG) 43.4 (344) / 41.8 (219)   
Presence of minor allel (CG,CC) 56.6 (449) / 58.2 (305) 0.54 0.893 (0.74-1.17) 
Total n case/cont 793 / 524   
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Figure legends 
Figure 1. Additive interaction between HLA and rs4774. 
Presence of HLA-DRB1*15 together with presence of minor allele (CG, CC) for 
rs4774 increases the odds ratio (OR) for MS. Error bars are 95% confidence interval 
of OR estimates. Attributable proportion (AP) due to interaction is the proportion of 
the incidence among individuals exposed to both associated factors compared with 
the factors individually. The AP value is significant if separated from zero. HLA is 
coded as presence of one or two alleles for HLA-DRB1*15, andrs4774 was coded as 
presence of minor allele (CG, CC). 
 
Figure 2. R2 plot showing the LD structure of investigated markers in the CIITA and 
CLEC16A gene in the MS cohort; darker gray indicates higher r2 between markers. 
(Haploview 4.2) 
 
Figure 3.  Meta-analysis in DRB1*15 stratified cases, presence of minor allele  
(CC, CG) for rs4774 and association to MS. 
 
Supplementary material 
S1. Genotyping and numbers in the different cohorts. 



